Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ocular And UroGen Team-Up With Drug-Makers On Drug-Delivery Hydrogels

Executive Summary

Ocular Therapeutix will work with Regeneron to create a sustained-release formulation of aflibercept for the treatment of wet age-related macular degeneration and other serious retinal diseases. On the same day, UroGen announced plans to work with Allergan on a hydrogel for controlled release delivery of drugs to the bladder.

You may also be interested in...



After Tocagen Thaws IPO Freeze, Verona And Zymeworks Bring April Total To Three

With three biopharma initial public offerings in April, the second quarter is on track to beat the first quarter's total of five IPOs – three in January and two in March – and several more are in the queue.

Regeneron Partnering With Ocular May Provide Needed Tech Validation

Regeneron is partnering with the troubled ophthalmology-focused biotech to develop a sustained-release formulation of Eylea that could enable a less-frequent dosing regimen.

Botox Adds Therapeutic Indication For Idiopathic Overactive Bladder

The FDA approval for idiopathic OAB follows a narrower indication for OAB related to neurological diseases such as multiple sclerosis or spinal cord injury.

Topics

Related Companies

UsernamePublicRestriction

Register

MT103969

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel